A Phase 3 interventional study of Ravulizumab and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals, Inc.. Completed at 51 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca — 3 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · AstraZeneca.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2017, is one of 12 in phase 3, and was the 16th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca are open now, in 8 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
Alexion Pharmaceuticals, Inc. · Sites in Canada, France, United Kingdom
Ages 12–17
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 12 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2017.
This study's enrollment of 202 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 26 across the 23 interventional studies, 75 across the 10 observational. Of the 26 that completed or were terminated, 18 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
1 of the studies in Hemoglobinuria, Paroxysmal by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449001Phase 3Alexion Pharmaceuticals, Inc.Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis | 2027-05-28 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who were clinically stable after having been treated with eculizumab for at least 6 months.
The study consisted of a 4-week Screening Period and a 26-week Randomized Treatment Period (Primary Evaluation Period). After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive ravulizumab for up to 4 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 4 years.
Biological: Ravulizumab
Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks. After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 4 years.
Biological: Ravulizumab · Biological: Eculizumab
All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
Also known as: ALXN1210, ULTOMIRIS
All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183
Lactate dehydrogenase (LDH) is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicates reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first study drug infusion. The percent change in LDH was analyzed using a mixed-effect model for repeated measures (MMRM) with the fixed, categorical effects of treatment, study visit, and study visit by treatment group interaction, as well as the continuous, fixed covariate of baseline LDH and the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1).
Time frame: Baseline, Day 183
Number Of Participants With Breakthrough Hemolysis Through Day 183
Breakthrough hemolysis (BTH) was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia \[hemoglobin \<10 grams (g)/deciliter (dL)\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the upper limit of normal (ULN).
Time frame: Baseline through Day 183
Change From Baseline To Day 183 In Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scores
FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline was defined as the last non-missing assessment value prior to first study drug dose. Change in FACIT-Fatigue score from Baseline to Day 183 was analyzed using an MMRM with the fixed, categorical effects of treatment, the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1), study visit, and study visit by treatment group interaction, as well as the continuous fixed covariate of Baseline FACIT-Fatigue score.
Time frame: Baseline, Day 183
Percentage Of Participants Who Achieved Transfusion Avoidance Through Day 183
Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 g/dL with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through Day 183.
Time frame: Baseline through Day 183
Percentage Of Participants With Stabilized Hemoglobin Levels Through Day 183
Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from Baseline in the absence of transfusion through Day 183.
Time frame: Baseline through Day 183
Number Of Participants With Breakthrough Hemolysis Through End of Study
BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia \[hemoglobin \<10 g/dL\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the ULN.
Time frame: Baseline through end of study (up to 4 years)
Change From Baseline To End of Study In FACIT-Fatigue Scores Through End of Study
FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline was defined as the last non-missing assessment value prior to first study drug dose. Change in FACIT-Fatigue score from Baseline to Day 183 was analyzed using an MMRM with the fixed, categorical effects of treatment, the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1), study visit, and study visit by treatment group interaction, as well as the continuous fixed covariate of Baseline FACIT-Fatigue score.
Time frame: Baseline, End of Study (up to 4 years)
Percentage Of Participants Who Achieved Transfusion Avoidance Through End of Study
Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 g/dL with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through the end of study.
Time frame: Baseline through end of study (up to 4 years)
Percentage Of Participants With Stabilized Hemoglobin Levels Through End of Study
Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from Baseline in the absence of transfusion through end of study.
Time frame: Baseline through end of study (up to 4 years)
| Milestone | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Started | 98 | 99 |
| Received at least 1 dose of study drug | 97 | 98 |
| Participants in the full analysis set (fas) | 97 | 98 |
| Completed | 96 | 95 |
| Not completed | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Randomized, not treated | 1 | 1 |
| Milestone | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Started | 96 | 95 |
| Completed | 92 | 88 |
| Not completed | 4 | 7 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Lactate dehydrogenase (LDH) is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria. A decrease in LDH indicates reduction (improvement) in hemolysis. Baseline was defined as the average of all available on-study assessments prior to the first study drug infusion. The percent change in LDH was analyzed using a mixed-effect model for repeated measures (MMRM) with the fixed, categorical effects of treatment, study visit, and study visit by treatment group interaction, as well as the continuous, fixed covariate of baseline LDH and the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1).
| percent change | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183 | -0.82 (-7.75 to 6.11) | 8.39 (1.47 to 15.32) |
Breakthrough hemolysis (BTH) was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia \[hemoglobin \<10 grams (g)/deciliter (dL)\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the upper limit of normal (ULN).
| number of participants | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Number Of Participants With Breakthrough Hemolysis Through Day 183 | 0 (0.00 to 3.73) | 5 (1.68 to 11.51) |
FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline was defined as the last non-missing assessment value prior to first study drug dose. Change in FACIT-Fatigue score from Baseline to Day 183 was analyzed using an MMRM with the fixed, categorical effects of treatment, the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1), study visit, and study visit by treatment group interaction, as well as the continuous fixed covariate of Baseline FACIT-Fatigue score.
| units on a scale | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Change From Baseline To Day 183 In Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scores | 2.01 (0.64 to 3.39) | 0.54 (-0.84 to 1.93) |
Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 g/dL with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through Day 183.
| percentage of participants | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Percentage Of Participants Who Achieved Transfusion Avoidance Through Day 183 | 87.6 (81.08 to 94.18) | 82.7 (75.16 to 90.15) |
Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from Baseline in the absence of transfusion through Day 183.
| percentage of participants | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Percentage Of Participants With Stabilized Hemoglobin Levels Through Day 183 | 76.3 (67.82 to 84.75) | 75.5 (67.00 to 84.02) |
BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia \[hemoglobin \<10 g/dL\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times the ULN.
| number of participants | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Number Of Participants With Breakthrough Hemolysis Through End of Study | 9 (4.38 to 17.05) | 6 (2.35 to 13.24) |
FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline was defined as the last non-missing assessment value prior to first study drug dose. Change in FACIT-Fatigue score from Baseline to Day 183 was analyzed using an MMRM with the fixed, categorical effects of treatment, the stratification randomization indicator of packed red blood cells transfusion history (yes/no within 12 months prior to Day 1), study visit, and study visit by treatment group interaction, as well as the continuous fixed covariate of Baseline FACIT-Fatigue score.
| units on a scale | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Change From Baseline To End of Study In FACIT-Fatigue Scores Through End of Study | -1.43 ± 5.694 | 0.00 ± 5.944 |
Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines (hemoglobin value of ≤9 g/dL with signs or symptoms of sufficient severity to warrant a transfusion, or a hemoglobin value of ≤7 g/dL regardless of presence of clinical signs or symptoms) through the end of study.
| percentage of participants | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Percentage Of Participants Who Achieved Transfusion Avoidance Through End of Study | 70.83 (60.67 to 79.67) | 70.53 (60.29 to 79.44) |
Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from Baseline in the absence of transfusion through end of study.
| percentage of participants | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab |
|---|---|---|
| Percentage Of Participants With Stabilized Hemoglobin Levels Through End of Study | 58.33 (47.82 to 68.32) | 67.37 (59.68 to 76.64) |
Collected over From Baseline (after first dose) to end of study (up to 4 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primary Evaluation Period (26 Weeks) Ravulizumab Treatment | 0/97 (0%) | 4/97 (4.1%) | 72/97 (74.2%) |
| Primary Evaluation Period (26 Weeks) Eculizumab Treatment | 0/98 (0%) | 8/98 (8.2%) | 85/98 (86.7%) |
| Extension Period (Ravulizumab To Ravulizumab) | 0/96 (0%) | 26/96 (27.1%) | 83/96 (86.5%) |
| Extension Period (Eculizumab to Ravulizumab) | 3/95 (3.2%) | 33/95 (34.7%) | 85/95 (89.5%) |
| Event | Primary Evaluation Period (26 Weeks) Ravulizumab Treatment | Primary Evaluation Period (26 Weeks) Eculizumab Treatment | Extension Period (Ravulizumab To Ravulizumab) | Extension Period (Eculizumab to Ravulizumab) |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/97 | 3/98 | 5/96 | 0/95 |
| HaemolysisBlood and lymphatic system disorders | 0/97 | 2/98 | 1/96 | 4/95 |
| InfluenzaInfections and infestations | 1/97 | 0/98 | 1/96 | 3/95 |
| InfectionInfections and infestations | 0/97 | 0/98 | 0/96 | 2/95 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 0/97 | 0/98 | 2/96 | 1/95 |
| CholelithiasisHepatobiliary disorders | 0/97 | 1/98 | 0/96 | 1/95 |
| Lower respiratory tract infectionInfections and infestations | 1/97 | 0/98 | 1/96 | 1/95 |
| AnaemiaBlood and lymphatic system disorders | 0/97 | 0/98 | 0/96 | 1/95 |
| PneumoperitoneumGastrointestinal disorders | 0/97 | 0/98 | 0/96 | 1/95 |
| ToothacheGastrointestinal disorders | 0/97 | 0/98 | 0/96 | 1/95 |
| Event | Primary Evaluation Period (26 Weeks) Ravulizumab Treatment | Primary Evaluation Period (26 Weeks) Eculizumab Treatment | Extension Period (Ravulizumab To Ravulizumab) | Extension Period (Eculizumab to Ravulizumab) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 20/97 | 20/98 | 27/96 | 21/95 |
| HeadacheNervous system disorders | 27/97 | 17/98 | 21/96 | 21/95 |
| Upper respiratory tract infectionInfections and infestations | 19/97 | 10/98 | 24/96 | 19/95 |
| FatigueGeneral disorders | 7/97 | 6/98 | 18/96 | 19/95 |
| NauseaGastrointestinal disorders | 8/97 | 9/98 | 13/96 | 16/95 |
| PyrexiaGeneral disorders | 9/97 | 2/98 | 15/96 | 16/95 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/97 | 10/98 | 16/96 | 12/95 |
| DizzinessNervous system disorders | 3/97 | 7/98 | 8/96 | 15/95 |
| DiarrhoeaGastrointestinal disorders | 9/97 | 7/98 | 15/96 | 14/95 |
| Back painMusculoskeletal and connective tissue disorders | 4/97 | 0/98 | 10/96 | 13/95 |
All participants who received at least 1 dose of study treatment (ravulizumab or eculizumab).
| Age, Continuous(years) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Total |
|---|---|---|---|
| Mean | 46.6 ± 14.41 | 48.8 ± 13.97 | 47.7 ± 14.19 |
| Sex: Female, Male(Participants) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Total |
|---|---|---|---|
| Female | 47 | 50 | 97 |
| Male | 50 | 48 | 98 |
| Ethnicity (NIH/OMB)(Participants) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 76 | 77 | 153 |
| Unknown or Not Reported | 18 | 17 | 35 |
| Race/Ethnicity, Customized(participants) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Total |
|---|---|---|---|
| White | 50 | 61 | 111 |
| Asian | 23 | 19 | 42 |
| Not Reported | 13 | 13 | 26 |
| Black or African American | 5 | 3 | 8 |
| Unknown | 3 | 1 | 4 |
| Other | 2 | 1 | 3 |
| Multiple | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in Feb 2022, 57 months.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 57 months is above that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →